Gracell Biotech launches $159m US IPO

By Jonathan Breen
05 Jan 2021

Chinese clinical-stage company Gracell Biotechnologies has kicked off the roadshow for its Nasdaq listing, eyeing up to $158.9m in proceeds.

The company focuses on discovering and developing cell therapies for cancer treatments, specifically addressing industry challenges and unmet medical needs. It is looking to raise capital to fund research and development.

A syndicate comprising Citi, Jefferies, Piper Sandler and Wells Fargo Securities are leading Gracell’s IPO, launched in ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial